Joana Dias

Dr. Joana Dias

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2018 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
AAAntonio Agudo
Antonio Agudo
VCValerie Cayssials
Valerie Cayssials
CBCatalina Bonet
Catalina Bonet
ATAnne Tjønneland
Anne Tjønneland
KOKim Overvad
Kim Overvad
PJPaula Jakszyn
Paula Jakszyn
Chronic inflammation plays a critical role in the pathogenesis of the 2 major types of gastric cancer. Several foods, nutrients, and nonnutrient food components seem to be involved in the regulation of chronic inflammation. We assessed the association between the inflammatory potential of the diet and the risk of gastric carcinoma, overall and for the 2 major subsites: cardia cancers and noncardia cancers. A total of 476,160 subjects (30% men, 70% women) from the European Investigation into Cancer and Nutrition (EPIC) study were followed for 14 y, during which 913 incident cases of gastric carcinoma were identified, including 236 located in the cardia, 341 in the distal part of the stomach (noncardia), and 336 with overlapping or unknown tumor site. The dietary inflammatory potential was assessed by means of an inflammatory score of the diet (ISD), calculated with the use of 28 dietary components and their corresponding inflammatory scores. The association between the ISD and gastric cancer risk was estimated by HRs and 95% CIs calculated by multivariate Cox regression models adjusted for confounders. The inflammatory potential of the diet was associated with an increased risk of gastric cancer. The HR (95% CI) for each increase in 1 SD of the ISD were 1.25 (1.12, 1.39) for all gastric cancers, 1.30 (1.06, 1.59) for cardia cancers, and 1.07 (0.89, 1.28) for noncardia cancers. The corresponding values for the highest compared with the lowest quartiles of the ISD were 1.66 (1.26, 2.20), 1.94 (1.14, 3.30), and 1.07 (0.70, 1.70), respectively. Our results suggest that low-grade chronic inflammation induced by the diet may be associated with gastric cancer risk. This pattern seems to be more consistent for gastric carcinomas located in the cardia than for those located in the distal stomach. This study is listed on the ISRCTN registry as ISRCTN12136108.

1 February 2019 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
SRStina Ramne
Stina Ramne
JDJoana Dias
Joana Dias
EGEsther González-Padilla
Esther González-Padilla
KOKjell Olsson
Kjell Olsson
BLBernt Lindahl
Bernt Lindahl
Emily SonestedtEmily Sonestedt
Emily Sonestedt
Although sugar consumption has been associated with several risk factors for cardiometabolic diseases, evidence for harmful long-term effects is lacking. In addition, most studies have focused on sugar-sweetened beverages (SSBs), not sugar per se. The aim of this study was to examine the associations between added and free sugar intake, intake of different sugar sources, and mortality risk. Two prospective population-based cohorts were examined: the Malmö Diet and Cancer Study (MDCS; n = 24,272), which collected dietary data by combining a food diary, interview, and food-frequency questionnaire (FFQ), and the Northern Swedish Health and Disease Study (NSHDS; n = 24,475), which assessed diet with an FFQ. Sugar intakes defined as both added and free sugar and different sugar sources were examined. The associations with mortality were examined using a multivariable Cox proportional hazards regression. Higher sugar consumption was associated with a less favorable lifestyle in general. The lowest mortality risk was found with added sugar intakes between 7.5% and 10% of energy (E%) intake in both cohorts. Intakes >20E% were associated with a 30% increased mortality risk, but increased risks were also found at intakes <5E% [23% in the MDCS and 9% (nonsignificant) in the NSHDS]. Similar U-shaped associations were found for both cardiovascular and cancer mortality in the MDCS. By separately analyzing the different sugar sources, the intake of SSBs was positively associated with mortality, whereas the intake of treats was inversely associated. Our findings indicate that a high sugar intake is associated with an increased mortality risk. However, the risk is also increased among low sugar consumers, although they have a more favorable lifestyle in general. In addition, the associations are dependent on the type of sugar source.

1 January 2015 in Atherosclerosis
Verified
Journal Article
Closed access
JDJoana Dias
Joana Dias
EWElisabet Wirfält
Elisabet Wirfält
IDIsabel Drake
Isabel Drake
BGBo Gullberg
Bo Gullberg
BHBo Hedblad
Bo Hedblad
HBHarry Björkbacka
Harry Björkbacka

8 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JDJoana Dias
Joana Dias
GFGunilla N. Fredrikson
Gunilla N. Fredrikson
UEUlrika Ericson
Ulrika Ericson
BGBo Gullberg
Bo Gullberg
BHBo Hedblad
Bo Hedblad
EWElisabet Wirfält
Elisabet Wirfält
Although cancer promotes inflammation, the role of inflammation in tumor-genesis is less well established. The aim was to examine if low-grade inflammation is related to post-menopausal breast cancer risk, and if obesity modifies this association. In the Malmö Diet and Cancer cohort, a nested case-control study was defined among 8,513 women free of cancer and aged 55–73 years at baseline (1991–96); 459 were diagnosed with invasive breast cancer during follow-up (until December 31st, 2010). In laboratory analyses of blood from 446 cases, and 885 controls (matched on age and date of blood sampling) we examined systemic inflammation markers: oxidized (ox)-LDL, interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α, white blood cells, lymphocytes and neutrophils. Odds ratios (OR) and 95% confidence intervals (CI) for breast cancer risk was calculated using multivariable conditional logistic regression. Inverse associations with breast cancer were seen in fully-adjusted models, for 2nd and 3rd tertiles of ox-LDL, OR (95% CI): 0.65 (0.47–0.90), 0.63 (0.45–0.89) respectively, p-trend = 0.01; and for the 3rd tertile of TNF-α, 0.65 (0.43–0.99), p-trend = 0.04. In contrast, those in the highest IL-1β category had higher risk, 1.71 (1.05–2.79), p-trend = 0.01. Obesity did not modify associations between inflammation biomarkers and breast cancer. Our study does not suggest that low-grade inflammation increase the risk of post-menopausal breast cancer.

10 November 2015 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JBJelena Bešević
Jelena Bešević
MGMarc J Gunter
Marc J Gunter
RFRenée Fortner
Renée Fortner
KTKonstantinos K Tsilidis
Konstantinos K Tsilidis
EWElisabete Weiderpass
Elisabete Weiderpass
MMMelissa A Merritt
Melissa A Merritt
Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521 330 total participants (approximately 370 000 women) aged 25–70 years at recruitment from 1992 to 2000. Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre. After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62–1.03) and a significant survival benefit in long-term MHT users (5 years use vs never use, HR=0.70, 95% CI=0.50–0.99, Ptrend=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk. Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.

29 November 2014 in The European Journal of Health Economics
Verified
Journal Article
Open access
PDF file
MLM. Lette
M. Lette
WBW. J. E. Bemelmans
W. J. E. Bemelmans
JBJoão Breda
João Breda
LSL. C. J. Slobbe
L. C. J. Slobbe
JDJoana Dias
Joana Dias
HBHendriek Boshuizen
Hendriek Boshuizen
This article presents a tool to calculate health care costs attributable to overweight in a comparable and standardized way. The purpose is to describe the methodological principles of the tool and to put it into use by calculating and comparing the costs attributable to overweight for The Netherlands, Germany and Czech Republic. The tool uses a top-down and prevalence-based approach, consisting of five steps. Step one identifies overweight-related diseases and age- and gender-specific relative risks. Included diseases are ischemic heart disease, stroke, hypertension, type 2 diabetes mellitus, colorectal cancer, postmenopausal breast cancer, endometrial cancer, kidney cancer and osteoarthritis. Step two consists of collecting data on the age- and gender-specific prevalence of these diseases. Step three uses the population-attributable prevalence to determine the part of the prevalence of these diseases that is attributable to overweight. Step four calculates the health care costs associated with these diseases. Step five calculates the costs of these diseases that are attributable to overweight. Overweight is responsible for 20–26 % of the direct costs of included diseases, with sensitivity analyses varying this percentage between 15–31 %. Percentage of costs attributable to obesity and preobesity is about the same. Diseases with the highest percentage of costs due to overweight are diabetes, endometrial cancer and osteoarthritis. Disease costs attributable to overweight as a percentage of total health care expenditures range from 2 to 4 %. Data are consistent for all three countries, resulting in roughly a quarter of costs of included diseases being attributable to overweight.